UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Radiofrequency ablation for early oesophageal squamous neoplasia: outcomes form United Kingdom registry.
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Journal Article
  • Authors:
    Haidry RJ, Butt MA, Dunn J, Banks M, Gupta A, Smart H, Bhandari P, Smith LA, Willert R, Fullarton G, John M, Di Pietro M, Penman I, Novelli M, Lovat LB
  • Publication date:
    28/09/2013
  • Pagination:
    6011, 6019
  • Journal:
    World J Gastroenterol
  • Volume:
    19
  • Issue:
    36
  • Status:
    Published
  • Country:
    United States
  • Language:
    eng
  • Keywords:
    Endoscopic mucosal resection, High-grade dysplasia, Oesophageal cancer, Radiofrequency ablation, Squamous neoplasia, Adult, Aged, Aged, 80 and over, Biopsy, Carcinoma, Squamous Cell, Catheter Ablation, Dilatation, Disease Progression, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Esophagoscopy, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Grading, Prospective Studies, Registries, Tertiary Care Centers, Time Factors, Treatment Outcome, United Kingdom
Abstract
AIM: To report outcomes on patients undergoing radiofrequency ablation (RFA) for early oesophageal squamous neoplasia from a National Registry. METHODS: A Prospective cohort study from 8 tertiary referral centres in the United Kingdom. Patients with squamous high grade dysplasia (HGD) and early squamous cell carcinoma (ESCC) confined to the mucosa were treated. Visible lesions were removed by endoscopic mucosal resection (EMR) before RFA. Following initial RFA treatment, patients were followed up 3 monthly. Residual flat dysplasia was treated with RFA until complete reversal dysplasia (CR-D) was achieved or progression to invasive Squamous cell cancer defined as infiltration into the submucosa layer or beyond. The main outcome measures were CR-D at 12 mo from start of treatment, long term durability, progression to cancer and adverse events. RESULTS: Twenty patients with squamous HGD/ESCC completed treatment protocol. Five patients (25%) had EMR before starting RFA treatment. CR-D was 50% at 12 mo with a median of 1 RFA treatment, mean 1.5 (range 1-3). Two further patients achieved CR-D with repeat RFA after this time. Eighty per cent with CR-D remain dysplasia free at latest biopsy, with median follow up 24 mo (IQR 17-54). Six of 20 patients (30%) progressed to invasive cancer at 1 year. Four patients (20%) required endoscopic dilatations for symptomatic structuring after treatment. Two of these patients have required serial dilatations thereafter for symptomatic dysphagia with a median of 4 dilatations per patient. The other 2 patients required only a single dilatation to achieve an adequate symptomatic response. One patient developed cancer during follow up after end of treatment protocol. CONCLUSION: The role of RFA in these patients remains unclear. In our series 50% patients responded at 12 mo. These figures are lower than limited published data.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
Author
Department of Targeted Intervention
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by